HSR Antitrust Waiting Period Terminated for Angelini Pharma Acquisition
CPRX sits 65% above its 52-week low of $19.05.
Summary
Catalyst Pharmaceuticals announced that the FTC granted early termination of the HSR Act waiting period, clearing a key regulatory condition for its acquisition by Angelini Pharma.
Key Events · M&A and Partnerships · CPRX
-
HSR Waiting Period Terminated
The FTC granted early termination of the Hart-Scott-Rodino Act waiting period on June 16, 2026, a critical step for the merger.
-
Merger Progress
This regulatory clearance advances the previously announced $4.1 billion acquisition by Angelini Pharma, which is expected to close in Q3 2026.
-
Shareholder Vote Pending
The merger remains subject to shareholder approval, with a special meeting scheduled for July 8, 2026.
Analysis · CPRX · Life Sciences
This 8-K announces that the U.S. Federal Trade Commission has granted early termination of the Hart-Scott-Rodino (HSR) Act waiting period for the proposed acquisition of Catalyst Pharmaceuticals by Angelini Pharma. This removes a significant regulatory hurdle, moving the $4.1 billion merger closer to completion. The transaction remains subject to shareholder approval, with a vote scheduled for July 8, 2026.
At the time of this filing, CPRX was trading at $31.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.8B. The 52-week trading range was $19.05 to $32.56. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.